Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Figure Technology Solutions Inc. Class A Common Stock (FIGR) vs Vir Biotechnology Inc. Common Stock (VIR) Price & Performance

Figure Technology Solutions Inc. Class A Common StockTrade
Vir Biotechnology Inc. Common StockTrade

Price performance (Past 24H)

Key statistics

Figure Technology Solutions Inc. Class A Common Stock vs Vir Biotechnology Inc. Common Stock — how do they compare? Figure Technology Solutions Inc. Class A Common Stock trades at $24.68 (market cap $6.11B), while Vir Biotechnology Inc. Common Stock trades at $10.2 (market cap $1.80B). The key difference: Figure Technology Solutions Inc. Class A Common Stock is far larger — about 3.4× Vir Biotechnology Inc. Common Stock's market cap, and Vir Biotechnology Inc. Common Stock is trading nearer its 52-week high, Figure Technology Solutions Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Figure Technology Solutions Inc. Class A Common Stock for 6 Days and Vir Biotechnology Inc. Common Stock for 0 Days on average.

FIGRVIR
Market Cap
$6.11B$1.80B
Volume
5,025,6041,782,836
Sector
FinancialsHealth
52-Week High
$73.91$11.78
52-Week Low
$24.91$5.12
Typical Hold Time
6 Days0 Days
Enterprise Value
$6.15B$1.36B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Figure Technology Solutions Inc. Class A Common Stock

FIGR trades at $27.25, down 4.25% over 24 hours, with a bearish technical signal from moving averages. The company reported strong fundamentals: Q2 2026 EPS beat expectations at $0.37, revenue grew to $509.30M in 2025, and net income margin improved to 33.83% in 2026. Recent news highlights the Kiavi acquisition and partnership with Sierra to enhance AI-driven lending capabilities, supporting growth in loan volumes.

Wall Street maintains a bullish outlook with a consensus price target of $50.00, implying significant upside. However, risks include recent earnings misses in Q4 2025 and Q1 2026, negative operating cash flow projected for 2026, and competitive pressures in the lending infrastructure space. The stock's high P/E of 28.52 warrants caution amid growth execution uncertainties.

Vir Biotechnology Inc. Common Stock

No Aura AI signal available yet.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

FIGR

No sentiment data available yet.

VIR
51% Buy49% Sell
Avg holding period · 0 Days

About Figure Technology Solutions Inc. Class A Common Stock

Figure Technology Solutions operates a blockchain-native capital marketplace. Its platform supports loan origination, funding, sale, and trading of tokenized assets, along with digital-asset infrastructure and services.

Read more on FIGR →

About Vir Biotechnology Inc. Common Stock

Vir Biotechnology, Inc. is a US clinical-stage biopharmaceutical company that develops monoclonal antibody-based medicines to treat and prevent serious infectious diseases.

Read more on VIR →